Aseptic meningitis is the inflammation on the protective membrane called ‘meninges’ covering the brain and spinal cord. Aseptic meningitis may be caused by infectious or non-infectious causes. Infectious causes include viral, bacterial, and rarely fungal. 80-90% of aseptic meningitis cases are caused by enteroviruses; but other causes include arboviruses, herpes viruses, measles, mumps, and human immunodeficiency virus. Non-infectious causes include drugs (including non-steroidal anti-inflammatory drugs, trimethoprim/sulfamethoxazole, intravenous immune globulin), sarcoidosis, vasculitis (caused by autoimmune diseases like lupus or Sjogren's syndrome), and malignancy, including metastases to the meninges. Most common symptoms includes fever, body ache, a painful headache, fatigue, and loss of appetite. It can occur at any age but is most common in children under the age of five. People with a weakened immune system caused by organ or bone marrow transplantation, disease, or medication (such as chemotherapy) or suffering from diabetes or AIDs are at enhanced risk of developing aseptic meningitis. The incidence of aseptic meningitis has been reported as 11 per 100,000 population per year. Depending on the type of cause, the male to female ratio may vary. Enteroviruses affects males 1.5 times more than females, while mumps virus affects males 3 times more than females. No specific treatment is available for aseptic meningitis. The patient is managed with supportive therapy. Treatment options may vary depending on specific causes. Most patients with aseptic meningitis completely recover with specific treatment within one to two weeks.
Based on treatment, the aseptic meningitis treatment market is segmented as antiviral (acyclovir, ganciclovir, foscavir, and valacyclovir), corticosteroids (dexamethasone, prednisone, and prednisolone), antibiotics (ceftriaxone, cefotaxime, gentamicin, and doxycycline), antifungal (amphotericin B, fluconazole, and flucytosine), and other supporting medications like IV fluids and anti-nausea agents. The antiviral segment is expected to expand followed by the antibiotic segment as 80-90% of aseptic meningitis cases are caused by viral infection. Based on molecule type, the aseptic meningitis treatment market is segmented into small molecules and biologics. Biologics segment is expected to expand as most researchers like Bristol-Myer Squib Company is focused on development of biologics like ipilimumab, nivolumab, and bevacizumab for treatment of aseptic meningitis. As no specific treatment is available to treat aseptic meningitis the main factor that drives aseptic meningitis treatment market. Additionally, increase in incidence of viral infections, increasing bone marrow transplants, and increase in use of chemotherapy are the factors that drive the aseptic meningitis treatment market. However, since the disease is managed by supportive medication and most patients recover from it, is a factor that restrains the growth of the aseptic meningitis treatment market.
In terms of geography, the aseptic meningitis treatment market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America dominates the aseptic meningitis treatment market, followed by Europe, due to the higher incidence rate of viral infections, increase in research and development expenditure, and availability of developed healthcare infrastructure. Asia Pacific is an emerging market for aseptic meningitis treatment due to the developing healthcare infrastructure, increase in patient awareness, and rising government expenditure in the healthcare industry. However, lack of proper treatment options and poor patient awareness are factors restraining the aseptic meningitis treatment market in regions such as Middle East & Africa.
Major players operating in the aseptic meningitis treatment market include Chiesi Farmaceutici S.p.A, Matinas BioPharma Holdings, Inc., Viamet Pharmaceuticals, Inc., Genentech, Inc., Pfizer. Inc. and Bristol-Myers Squibb Company.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.